M K Nisar1. 1. Rheumatology Department, Luton and Dunstable University Hospital NHSFT, Lewsey Road, Luton, LU4 0DZ, UK. drnisar12@yahoo.co.uk.
Abstract
INTRODUCTION: Early arthritis clinics (EACs) have been well established since 1980s. Most of the data for their effectiveness comes from rheumatoid arthritis (RA) management and is largely limited to process outcomes. There is little evidence that such clinics improve clinical outcomes particularly for psoriatic arthritis (PsA). We examined whether EACs provide better outcomes irrespective of final arthritis diagnosis. METHODS: A 52-week prospective observational study of all inflammatory arthritis patients presenting to early arthritis service at our secondary care hospital in 2016 was undertaken. A protocolised approach to the early initiation of therapy (within 3 weeks) and 6-weekly review of treatment outcomes was embedded irrespective of the arthritis diagnosis. Statistical analysis was undertaken using Mann-Whitney U test for disease activity scores to ascertain the significance of outcomes. RESULTS: Of 1884 patients referred, 482 (25.5%) were triaged into EACs based on set criteria. 159 (64.3%) had RA, 55 (22%) with PsA and 33 had other inflammatory arthritides. Mean DAS28 for RA at first visit was 4.65 (0.6-8.0). Treating to target achieved DAS28 remission for 84 (53.5%) and low disease activity (LDA) for a further 44 (34%). Median time to achieve remission or LDA was 20 weeks (0-52 weeks). Mean tender (TJ) and swollen joint (SJ) counts for PsA at first visit were 8.2 (1-35) and 3.5 (0-14), respectively [n = 55]. The patient (PtGA) and physician (PhGA) global assessments mean were 3.0 and 2.9 (1-5). Target [TJ and SJ ≤ 2] was achieved for 38 patients (69%) and good PsARC response for a further four (7%). Median time to achieve the target or good response was 22 weeks (0-48 weeks). Final TJ and SJ mean was significantly better at 1.2 (0-4) and 0.3 (0-2) [p < 0.0001] with similar improvement in PtGA [mean 1.8 (1-4)] and PhGA [mean 1.6 (1-3)]. CONCLUSION: Dedicated EACs help achieve good clinical outcomes in majority of patients with RA and PsA. Nearly 80% of our cohort attained the target or good disease response in less than 6 months. This was despite a significant delay in patients presenting to their GPs and moderately high disease activity.
INTRODUCTION: Early arthritis clinics (EACs) have been well established since 1980s. Most of the data for their effectiveness comes from rheumatoid arthritis (RA) management and is largely limited to process outcomes. There is little evidence that such clinics improve clinical outcomes particularly for psoriatic arthritis (PsA). We examined whether EACs provide better outcomes irrespective of final arthritis diagnosis. METHODS: A 52-week prospective observational study of all inflammatory arthritispatients presenting to early arthritis service at our secondary care hospital in 2016 was undertaken. A protocolised approach to the early initiation of therapy (within 3 weeks) and 6-weekly review of treatment outcomes was embedded irrespective of the arthritis diagnosis. Statistical analysis was undertaken using Mann-Whitney U test for disease activity scores to ascertain the significance of outcomes. RESULTS: Of 1884 patients referred, 482 (25.5%) were triaged into EACs based on set criteria. 159 (64.3%) had RA, 55 (22%) with PsA and 33 had other inflammatory arthritides. Mean DAS28 for RA at first visit was 4.65 (0.6-8.0). Treating to target achieved DAS28 remission for 84 (53.5%) and low disease activity (LDA) for a further 44 (34%). Median time to achieve remission or LDA was 20 weeks (0-52 weeks). Mean tender (TJ) and swollen joint (SJ) counts for PsA at first visit were 8.2 (1-35) and 3.5 (0-14), respectively [n = 55]. The patient (PtGA) and physician (PhGA) global assessments mean were 3.0 and 2.9 (1-5). Target [TJ and SJ ≤ 2] was achieved for 38 patients (69%) and good PsARC response for a further four (7%). Median time to achieve the target or good response was 22 weeks (0-48 weeks). Final TJ and SJ mean was significantly better at 1.2 (0-4) and 0.3 (0-2) [p < 0.0001] with similar improvement in PtGA [mean 1.8 (1-4)] and PhGA [mean 1.6 (1-3)]. CONCLUSION: Dedicated EACs help achieve good clinical outcomes in majority of patients with RA and PsA. Nearly 80% of our cohort attained the target or good disease response in less than 6 months. This was despite a significant delay in patients presenting to their GPs and moderately high disease activity.
Entities:
Keywords:
Clinic; Early arthritis; Outcomes; Psoriatic arthritis
Authors: L R Lard; H Visser; I Speyer; I E vander Horst-Bruinsma; A H Zwinderman; F C Breedveld; J M Hazes Journal: Am J Med Date: 2001-10-15 Impact factor: 4.965
Authors: B Combe; R Landewe; C Lukas; H D Bolosiu; F Breedveld; M Dougados; P Emery; G Ferraccioli; J M W Hazes; L Klareskog; K Machold; E Martin-Mola; H Nielsen; A Silman; J Smolen; H Yazici Journal: Ann Rheum Dis Date: 2006-01-05 Impact factor: 19.103
Authors: Bernard Combe; Robert Landewe; Claire I Daien; Charlotte Hua; Daniel Aletaha; Jose María Álvaro-Gracia; Margôt Bakkers; Nina Brodin; Gerd R Burmester; Catalin Codreanu; Richard Conway; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Joao Fonseca; Karim Raza; Lucía Silva-Fernández; Josef S Smolen; Diana Skingle; Zoltan Szekanecz; Tore K Kvien; Annette van der Helm-van Mil; Ronald van Vollenhoven Journal: Ann Rheum Dis Date: 2016-12-15 Impact factor: 19.103
Authors: Laura C Coates; Arthur Kavanaugh; Philip J Mease; Enrique R Soriano; Maria Laura Acosta-Felquer; April W Armstrong; Wilson Bautista-Molano; Wolf-Henning Boehncke; Willemina Campbell; Alberto Cauli; Luis R Espinoza; Oliver FitzGerald; Dafna D Gladman; Alice Gottlieb; Philip S Helliwell; M Elaine Husni; Thorvardur J Love; Ennio Lubrano; Neil McHugh; Peter Nash; Alexis Ogdie; Ana-Maria Orbai; Andrew Parkinson; Denis O'Sullivan; Cheryl F Rosen; Sergio Schwartzman; Evan L Siegel; Sergio Toloza; William Tuong; Christopher T Ritchlin Journal: Arthritis Rheumatol Date: 2016-03-23 Impact factor: 10.995
Authors: Laura C Coates; Nuria Navarro-Coy; Sarah R Brown; Sarah Brown; Lucy McParland; Howard Collier; Emma Skinner; Jennifer Law; Anna Moverley; Sue Pavitt; Claire Hulme; Paul Emery; Philip G Conaghan; Philip S Helliwell Journal: BMC Musculoskelet Disord Date: 2013-03-21 Impact factor: 2.362
Authors: Cristina Regueiro; Laura Nuño; Ana Triguero-Martinez; Ana M Ortiz; Alejandro Villalba; María Dolores Bóveda; Ana Martínez-Feito; Carmen Conde; Alejandro Balsa; Isidoro González-Alvaro; Antonio Gonzalez Journal: Sci Rep Date: 2021-05-11 Impact factor: 4.379